Objective
To evaluate the association between fibroblast growth factor receptor 2 (FGFR2) rs2981582 polymorphism and the risk of breast cancer in Chinese population.
Methods
PubMed, Embase, Cochrane Library, Chinese Science and Technology Academic Journal, Chinese Biomedical Literature Database, Chinese Journal Full-Text Database, and Wanfang Database were searched to identify relevant articles that investigated the association of FGFR2 rs2981582 polymorphism with breast cancer risk from their inception to March 2018. A meta-analysis was performed by using the Stata 12.0 software.
Results
A total of 11 case-control studies were included in the present meta-analysis, including 5 921 breast cancer cases and 5 909 healthy controls. The pooled results indicated that, there was significant association between FGFR2 rs2981582 polymorphism and susceptibility of breast cancer in Chinese population under allele model ［C vs. T: OR=1.07, 95% CI was (1.01, 1.14), P=0.027］, heterozygote model ［CC vs. CT: OR=1.12, 95% CI was (1.01, 1.24), P=0.026］, homozygous model ［CC vs. TT: OR=1.19, 95% CI was (1.05, 1.34), P=0.005］, dominant model ［CC vs. CT+TT: OR=1.10, 95% CI was (1.00, 1.21), P=0.040］, and recessive model ［TT vs. CC+CT: OR=1.19, 95% CI was (1.10, 1.30), P<0.001］.
Conclusion
FGFR2 rs2981582 polymorphism was associated with the risk of breast cancer in Chinese population.
ObjectiveTo systematically review the current clinical research status of major therapeutic targets and research advances in emerging targets for targeted therapy in advanced gastric cancer, so as to provide a reference for clinical precision therapy. MethodThe key studies on major therapeutic targets for targeted therapy are reviewed, including HER2 (human epidermal growth factor receptor 2), VEGFR2 (vascular endothelial growth factor receptor 2), Claudin 18.2, FGFR2b (fibroblast growth factor receptor 2b), DKK1 (Dickkopf-related protein 1), and MET (mesenchymal to epithelial transition) factor. ResultsClinical research and application of anti-HER2 agents have been well established, and such agents have been utilized throughout the entire course from the first-line to later-line therapy. VEGFR2 inhibitors have been positioned as core treatments in the second-line and subsequent-line settings. The emergence of targeted therapy against Claudin 18.2 has provided the new first-line option for patients with HER2-negative advanced gastric cancer. Investigations into agents targeting targets, including FGFR2b, DKK1, and MET, have been continuously intensified. Conclusions Currently, survival of patients with advanced gastric cancer can be improved by targeted therapy. However, several challenges remain to be addressed, including heterogeneous target expression, complex resistance mechanisms, and uncertainty regarding the optimal treatment strategy. Further investigations are warranted in dynamic monitoring and standardization of target detection, clarification of resistance mechanisms and optimization of combination strategies, as well as sequencing of therapeutic agents and individualized treatment selection.
